Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.325
-0.105 (-4.32%)
Oct 6, 2026, 10:45 AM EDT - Market open
Fate Therapeutics Employees
Fate Therapeutics had 161 employees as of December 31, 2025. The number of employees decreased by 20 or -11.05% compared to the previous year.
Employees
161
Change (1Y)
-20
Growth (1Y)
-11.05%
Revenue / Employee
$40,317
Profits / Employee
-$782,584
Market Cap
278.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -20 | -11.05% |
| Dec 31, 2024 | 181 | 0 | - |
| Dec 31, 2023 | 181 | -370 | -67.15% |
| Dec 31, 2022 | 551 | 102 | 22.72% |
| Sep 30, 2022 | 545 | 155 | 39.74% |
| Jun 30, 2022 | 542 | 186 | 52.25% |
| Mar 31, 2022 | 511 | 197 | 62.74% |
| Dec 31, 2021 | 449 | 170 | 60.93% |
| Sep 30, 2021 | 390 | 111 | 39.78% |
| Jun 30, 2021 | 356 | - | - |
| Mar 31, 2021 | 314 | 136 | 76.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| EyePoint | 214 |
| Rocket Pharmaceuticals | 202 |
| Scribe Therapeutics | 82 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 63 |
| X4 Pharmaceuticals | 45 |
FATE News
- 4 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewsWire
- 11 days ago - Fate Therapeutics announces CIRM awarded it a $15M grant - TheFly
- 11 days ago - Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - GlobeNewsWire
- 20 days ago - Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewsWire
- 27 days ago - Fate Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 27 days ago - Fate Therapeutics announces clinical data from FT819 study - TheFly
- 27 days ago - Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting - GlobeNewsWire